Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGOMA study of regorafenib in relapsed glioblastoma
2014-003722-41Phase 2Completed
- Sponsor
- Istituto Oncologico Veneto
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of regorafenib in glioblastoma (GBM) (2 arms), sponsored by Istituto Oncologico Veneto. Primary endpoint: Overall survival. Started Jan 2015; status: completed.
02
Drugs
regorafenib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2014-003722-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003722-41.